NCT04804111View on ClinicalTrials.gov

Study of of URC102 to Assess the Efficacy and Safety in Gout Patients

PHASE2CompletedINTERVENTIONAL

Enrollment

171

Participants

Timeline

Start Date

January 21, 2019

Primary Completion Date

September 4, 2020

Study Completion Date

November 29, 2020

Conditions

Gout

Interventions

DRUG

arm 0

placebo group

DRUG

arm 1

3 mg of the URC102 group

DRUG

arm 2

6 mg of the URC102 group

DRUG

arm 3

9 mg of the URC102 group

DRUG

arm 4

Febuxostat 80 mg

Trial Locations (2)

06725

JW Pharmaceutical, Seoul

Unknown

Chung-Ang University Hospital, Seoul

Sponsors

Lead Sponsor

JW Pharmaceutical

All Listed Sponsors

lead

JW Pharmaceutical

INDUSTRY